more_reports

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

  ()
Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

  ()
Doximity Inc. (DOCS:NYSE) reported 7% revenue growth as workflow active prescribers increased more than 30% year over year and AI Search queries climbed more than 25% quarter over quarter.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

Virtual Care AI Provider Expands Potential Access to 100k+ New York Covered Lives

  ()
Rocket Doctor AI expanded potential in-network access to more than 100,000 additional eligible covered lives in New York through a new payer agreement, while continuing to expand its physician network and healthcare AI capabilities in the United States.
Tags: Biotechnology / PharmaceuticalsHealthcare ServicesArtificial Intelligence

Virtual Care Network Expands to Include 100,000 More New Yorkers, Reaching 24 Million Nationwide

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) recently added 100,000 eligible members in New York to its network. This expansion brings the total number of individuals with potential in-network access to the company's virtual care services to approximately 10 million in New York and 24 million across the United States.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom

Research Report
  ()
The company's flagship gene therapy posted a fifth consecutive sequential decline in 2Q26, with DM1 and FSHD data updates seen as the next potential value inflection points.
Tags: Biotechnology / Pharmaceuticals

AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%

  ()
DarioHealth reported Q2 revenue of $5.2 million with gross margin rising to 62 percent and contracted ARR reaching $13.1 million after signing a fifth Fortune 50 client and expanding provider-backed care.
Tags: Life Sciences Tools & Diagnostics

DarioHealth Reports Q2 Revenue, with 62% Gross Margin as AI Platform Expands

  ()
DarioHealth Corp. (DRIO:NASDAQ) reported US$5.2 million in Q2 revenue, a 62% gross margin and US$13.1 million in contracted and late-stage ARR.
Tags: Life Sciences Tools & Diagnostics

GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review

  ()
GRAIL Inc. prepares for its Sept. 23 FDA advisory committee meeting on the Galleri MCED test PMA, backed by large clinical studies and growing commercial revenue in the expanding multi-cancer early detection market.
Tags: Life Sciences Tools & Diagnostics

Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review

  ()
GRAIL Inc. (GRAL:NASDAQ) announces that an FDA committee will meet in September to evaluate the Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test. Read why one financial expert thinks it will gain approval.
Tags: Life Sciences Tools & Diagnostics

Digital Health Provider Launches Women's Health and Sleep Solutions

  ()
DarioHealth expands its cardiometabolic platform with Dario Women and Dario Sleep programs. Revenue contribution expected late 2026 amid rising demand for multi-condition digital care solutions.
Tags: Healthcare Services

AI Health Platform Expands Into Women's Health and Sleep With New Revenue Expected in Q4

  ()
DarioHealth Corp. (DRIO:NASDAQ) launched Dario Women and Dario Sleep, expanding its provider-backed cardiometabolic platform with programs expected to begin contributing recurring revenue in the fourth quarter.
Tags: Healthcare Services

Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial

  ()
Evommune begins Phase 2b testing of oral MRGPRX2 antagonist EVO756 for migraine prevention. The placebo-controlled study targets 330 patients with doses up to 100 mg and reports data in 2027.
Tags: Biotechnology / Pharmaceuticals

Myelofibrosis Combo Advances as Karyopharm Preps August sNDA

  ()
Karyopharm Therapeutics plans an sNDA filing for selinexor plus ruxolitinib in myelofibrosis. SVR35 endpoint and Phase 3 SENTRY data support the accelerated approval path.
Tags: Biotechnology / Pharmaceuticals

Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market

  ()
Sarepta Therapeutics contends with an FDA clinical hold on Elevidys following safety signals, while the Duchenne muscular dystrophy market projects strong growth through 2030.
Tags: Biotechnology / Pharmaceuticals

NY Telehealth Extension Advances Rocket Doctor AI Platform

  ()
Rocket Doctor AI extends its New York telehealth engagement through 2029, combining grants and Medicaid to serve underserved patients while scaling its AI platform amid strong digital health market growth.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

PFAS Treatment System Processes 2 Million Gallons at New Jersey Site

  ()
BioLargo's AEC technology has treated over 2 million gallons of PFAS-contaminated water in New Jersey while meeting regulatory standards. Learn how the system reduces waste and costs compared with traditional methods.
Tags: CleantechTechnologySpecial Situations

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

This AI Healthcare Platform Is Taking Its New York Expansion Through 2029

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

Cleantech Company Delivers PFAS Removal Breakthrough in New Jersey

  ()
BioLargo Inc. (BLGO:OTCQX) announces the processing of more than 2 million gallons of PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) technology. Find out why one technical analyst likes BLGO's business model.
Tags: CleantechTechnologySpecial Situations

Evommune Doses First Patient in Migraine Trial

  ()
Evommune Inc. (EVMN:NYSE) dosed its first patient in a Phase 2b trial of EVO756, an oral migraine prevention drug targeting the MRGPRX2 receptor.
Tags: Biotechnology / Pharmaceuticals

Karyopharm Pursues Myelofibrosis FDA Milestone

  ()
Karyopharm Therapeutics Inc. (KPTI:NASDAQ) prepares an FDA filing for selinexor plus ruxolitinib after Phase 3 results, targeting the first approved combination therapy for myelofibrosis.
Tags: Biotechnology / Pharmaceuticals

Sarepta Grants New CEO 2.2M Stock Options Amid "Sell" Rating

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) granted CEO Michael Severino options for 2,224,342 shares and 756,104 RSUs as an inducement award tied to his hiring.
Tags: Biotechnology / Pharmaceuticals